Skip to main content
SpringerLink
Log in

Gene Therapy

  • Chapter
  • First Online:
Basic and Applied Aspects of Biotechnology

  • 2466 Accesses

Abstract

Genes are regions on chromosomes which carry specific information for the production of proteins. Advancement in science, especially in medical research, has led to the identification and isolation of genes responsible for human diseases. A person carrying the defect in a specific gene might develop disease, which may be inheritable. In gene therapy, nucleic acid is the therapeutic agent. In this, the defective genes responsible for the disease are genetically modified in patients in order to achieve a therapeutic goal and return the individual to good health. The therapy is achieved by using a viral vector or gene delivery vehicles. The steps involved in the therapy in which the gene of interest enters the target cell via viral vector and begins expression are referred to as transduction. Gene therapy can be used to treat diseases caused by mutations in the patient’s own DNA (inherited disorders, cancers) as well as infectious diseases and is particularly valuable in cases where no conventional treatment exists or where that treatment is inherently risky.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 249.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Aartsma-Rus A, Ommen GJV (2007) Antisense-mediated exon skipping: a versatile tool with therapeutic and research applications. RNA 13:1609–1624

    Article  CAS  Google Scholar 

  2. Aiuti A et al (2009) Gene therapy for immunodeficiency due to adenosine deaminase deficiency. N Engl J Med 360:447–458

    Article  CAS  Google Scholar 

  3. Al-Dosari MS, Gao X (2009) Nonviral gene delivery: principle, limitations, and recent progress. AAPS J 11:671–681

    Article  CAS  Google Scholar 

  4. Carroll D, Morton JJ, Beumer KJ, Segal DJ (2006) Design, construction and in vitro testing of zinc finger nucleases. Nat Protoc 1:1329–1341

    Article  CAS  Google Scholar 

  5. Cavazzana-Calvo et al (2000) Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. Science 28:669–672

    Google Scholar 

  6. Cavazzana-Calvo M, Fischer A (2007) Gene therapy for severe combined immunodeficiency: are we there yet? J Clin Invest 117:1456–1465

    Article  CAS  Google Scholar 

  7. Cotrim AP, Baum BJ (2008) Gene therapy: some history, applications, problems and prospects. Toxicol Pathol 36:97–103

    Article  CAS  Google Scholar 

  8. Deutekom et al (2007) Local dystrophin restoration with antisense oligonucleotide PRO051. N Engl J Med 357:2677–2686

    Article  Google Scholar 

  9. Edelstein ML, Abedi MR, Wixon J, Edelstein RM (2004) Gene therapy clinical trials worldwide 1989–2004 – an overview. J Gene Med 6:597–602

    Article  Google Scholar 

  10. Edelstein ML, Abedi MR, Wixon J (2007) Gene therapy clinical trials worldwide to 2007-an update. J Gene Med 9:833–842

    Article  Google Scholar 

  11. Fischer A et al (2004) LM02 and gene therapy for severe combined immunodeficiency. N Engl J Med 350:2526–2527

    Article  CAS  Google Scholar 

  12. Gene Therapy Advisory Committee 12th Annual Report (pages 10 and 13–15). Available: http://www.advisorybodies.doh.gov.uk/genetics/gtac/GTAC12thannualReport.pdf

  13. Gene therapy clinical trials worldwide (2006) J Gene Med, New Jersey, Wiley www.abedia.com/wiley/indications.php

  14. Ginn SL et al (2013) Gene therapy clinical trials worldwide to 2012-an update. J Gene Med 15:65–77

    Article  CAS  Google Scholar 

  15. Hacein-Bey-Abina S, von Kalle C, Schmidt M et al (2003) A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency. N Engl J Med 348:255–256

    Article  Google Scholar 

  16. Kasper DL, Braunwald E, Fauci AS, Hauser SL, Longo DL, Jameson JL (eds) (2008) Harrison’s principles of internal medicine, 17th edn. Mc Graw-Hill Medical publishers, New York

    Google Scholar 

  17. Hausen P, Stein H (1970) Ribonuclease H—an enzyme degrading enzymes with zinc finger DNA-recognition domains. Eur J Biochem 14:278–283

    Article  CAS  Google Scholar 

  18. Herzog RW (2010) Gene therapy for SCID-X1: round 2. Mol Ther 18:1891

    Article  CAS  Google Scholar 

  19. Kim YG, Cha J, Chandrasegaran S (1996) Hybrid restriction enzymes: zinc finger fusions to Fok I cleavage domain. Proc Natl Acad Sci U S A 93:1156–1160

    Article  CAS  Google Scholar 

  20. Kim S, Lee MJ, Kim H, Kang M, Kim JS (2011) Preassembled zinc-finger arrays for rapid construction of ZFNs. Nat Methods 8:7

    Article  CAS  Google Scholar 

  21. Kurreck J (2003) Antisense technologies. Improvement through novel chemical modifications. Eur J Biochem 270:1628–1644

    Article  CAS  Google Scholar 

  22. Leiden JM (1995) Gene therapy—promise, pitfalls, and prognosis. N Engl J Med 28:871–873

    Article  Google Scholar 

  23. Lin E, Nemunaitis J (2004) Oncolytic viral therapies. Cancer Gene Ther 11:643

    Article  CAS  Google Scholar 

  24. Manno et al (2006) Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response. Nat Med 12:342–347

    Article  CAS  Google Scholar 

  25. Marwick C (1998) First “antisense” drug will treat CMV retinitis. JAMA 280:871

    Article  CAS  Google Scholar 

  26. Otto et al (2006) Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1. Nat Med 12:401–409

    Article  Google Scholar 

  27. Papworth M, Kolasinska P, Minczuk M (2006) Designer zinc-finger proteins and their applications. Gene 366:27–38

    Article  CAS  Google Scholar 

  28. Pearson H (2008) Protein engineering: the fate of fingers. Nature 455:160–164

    Article  CAS  Google Scholar 

  29. Raper SE, Chirmule N, Lee FS et al (2003) Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer. Mol Genet Metab 80:148–158

    Article  CAS  Google Scholar 

  30. Sadelain M et al (2003) Targeting tumours with genetically enhanced T lymphocytes. Nat Rev Cancer 3:35

    Article  CAS  Google Scholar 

  31. Scaffidi P, Misteli T (2005) Reversal of the cellular phenotype in the premature aging disease Hutchinson–Gilford progeria syndrome. Nat Med 11:440–445

    Article  CAS  Google Scholar 

  32. Shah PB, Losordo DW (2005) Non-viral vectors for gene therapy. Clinical trials in cardiovascular disease. Adv Genet 54:339–361

    CAS  Google Scholar 

  33. Smith J, Bibikova M, Whitby FG, Reddy AR, Chandrasegaran S, Carroll D (2000) Requirements for double-strand cleavage by chimeric restriction enzymes with zinc finger DNA-recognition domains. Nucleic Acids Res 28:3361–3369

    Article  CAS  Google Scholar 

  34. Stein et al (2010) Genomic instability and myelodysplasia with monosomy 7 consequent to EVI1 activation after gene therapy for chronic granulomatous disease. Nat Med 16:198–204

    Article  CAS  Google Scholar 

  35. Takefman D, Bryan W (2012) The state of gene therapies: the FDA perspective. Mol Ther 20:877–878

    Article  CAS  Google Scholar 

  36. Zamecnik PC, Stephenson ML (1978) Inhibition of Rous sarcoma virus replication and cell transformation by a specific oligodeoxynucleotide. Proc Natl Acad Sci 75:280–284

    Article  CAS  Google Scholar 

Some Selected Resources

Download references

Author information

Authors and Affiliations

  1. Institute of Biosciences and Biotechnology, Chhatrapati Shahu Ji Maharaj University, Kanpur, UP, India

    Varsha Gupta

  2. George Washington University, Washington DC, USA

    Manjistha Sengupta

  3. Orthopaedics Unit, Community Health Centre, Kanpur, UP, India

    Jaya Prakash

  4. School of Life sciences, Jawaharlal Nehru University, New Delhi, India

    Baishnab Charan Tripathy

Authors
  1. Varsha Gupta
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Manjistha Sengupta
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jaya Prakash
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Baishnab Charan Tripathy
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 2017 Springer Science+Business Media Singapore

About this chapter

Cite this chapter

Gupta, V., Sengupta, M., Prakash, J., Tripathy, B.C. (2017). Gene Therapy. In: Basic and Applied Aspects of Biotechnology. Springer, Singapore. https://doi.org/10.1007/978-981-10-0875-7_17

Download citation

Publish with us

Policies and ethics

Search

Navigation